Dr. Reddy's Laboratories Ltd. 500124 shares slid 1.27% to 1,354.20 Indian rupees Friday, on what proved to be an all-around ...
Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Geode Capital Management LLC increased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 109.3% ...
Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...
Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.49 and traded ...
Stocks like Tata Steel, Dr Reddy’s Laboratories, WPIL, Rail Vikas Nigam, Mahindra and Mahindra, Mankind Pharma, CESC, ...